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ABSTRACT:  
Cocrystallization studies on Naringenin with 27 coformers have led to the formation of five 
new solid forms: piperazinium salt (PIP+-NR-) and four cocrystals with the coformers flavone 
(FLV), 4-hydroxypyridine (4-HP), anthranilamide (ATA), and 4,4′-bipyridine (Bipy). 
Structural characterization reveals that the hydrogen bonded head to tail dimer motif in 
naringenin is maintained only in the cocrystal with flavone (NR-FLV). All four neutral 
cocrystals maintain the S(6) O−H···O=C intramolecular hydrogen bond seen in naringenin 
with this carbonyl oxygen atom bifurcated. The piperazinium salt is the only structure in 
which the ether oxygen is involved in hydrogen bonding. Some of the structures display 
disorder in the chiral center of naringenin, making them anomalous racemic solid solutions. 
The solubility study revealed that the salt formation has significantly enhanced the solubility 
of naringenin, for example the piperazinium salt has enhanced solubility of >3,000 times that 
of the neutral parent compound. 
Introduction:  
Flavonoids are of considerable interest due to their abundant availability in various dietary 
substances like fruits, vegetables, nuts, and beverages such as coffee, tea, and red wine, as 
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well as in medicinal herbs.1 It has been proven that they can act as effective scavengers of 
radicals in vitro,2-3 and they have potential health benefits such as cardioprotection,4-6 
cerebrovascular and neuroprotection7-9 as well as chemoprevention.10 It is estimated that the 
daily oral dietary intake of the flavonoids is about 0.5-1.0 g in Western countries.11 However, 
due to their poor solubility and bioavailability, it is difficult to formulate them in any 
potential medicine. One way to ameliorate the solubility of poorly-soluble APIs is the use of 
multi-component forms such as salts and cocrystals. Co-crystallization is evolving as an 
excellent paradigm to modulate/improve the physicochemical properties substantially by 
using non-covalent interactions. Cocrystallization can alter various properties such as melting 
point, stability, solubility, dissolution, friability, density and bioavailability of active 
pharmaceutical ingredient in a controlled way.12-17 Converting a compound into a salt is a 
well-known conventional method in the pharmaceutical sector to improve various properties 
and it is estimated that over half of the medicines on the market are administered as salts.18-20 
Converting flavones into their corresponding salts is challenging due to the weakly acidic 
phenolic functional groups. 
 
Figure 1. Molecular structure of naringenin (NR). A, B and C corresponds to the commonly 
used notation for numbering the rings in naringenin22 
Naringenin (NR) is a flavonoid widely available in citrus and tomato peel, Figure 1.21 It 
exhibits a variety of biological activities including anti-inflammatory,23 anti-oxidant,24 anti-
potent,25-26 anti-allergetic,27 phytoestrogenic,28 anti-atherogenic,29 and anti-ulcer activity.30-33 
Naringin is a glycoside of naringenin that readily hydrolyses in the intestinal epithelium to 
give naringenin.34 However naringenin is reported to have very low solubility35 and 
bioavailability36 issues and, therefore, it was selected for this study.   
To date, only three crystal structures associated with naringenin have been published in the 
literature. The first two are the structures of (±)-naringenin (CSD REFCODE is DOLRIF) 37 
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and of the (±) solid solution (DOLRIF01).38 The last structure is a salt with 
diazobicyclooctane (COLHER).39 
In this study, a total of 27 different coformers selected from a selection of nutraceuticals, 
drugs, generally recognized as safe (GRAS) and non-GRAS molecules were investigated for 
their ability to form a cocrystal or salt with naringenin, as shown in Figure 2 [carboxylic 
acids (top), N-substituted heterocycles (middle) and neutral compounds (bottom)].  
Five novel forms were discovered. Four of the forms are cocrystals; namely naringenin with 
flavone (NR-FLV, 18), 4-hydroxypyridine (NR-4HP, 11), anthranilamide (NR-ATA, 27) and 
4,4′-dipyridyl (NR-Bipy, 10). The fifth form is a salt with piperazine (PIP+-NR-, 13). 
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Figure 2 Coformers investigated in this study: nutraceuticals and GRAS coformers (blue), 
drugs (green), non-GRAS coformers (black), and the coformers which formed cocrystals with 
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Naringenin was purchased from TCI chemicals, all the coformers and HPLC solvents were 
purchased from Sigma Aldrich and were used as received without further purification.  
Grinding experiments 
Mechanical grinding experiments were conducted in a Retsch MM400 Mixer mill, equipped 
with stainless steel 5 mL grinding jars and one 2.5 mm stainless steel grinding ball per jar. 
The mill was operated at a rate of 30 Hz for 30 min. The ratio of 1:1 of Naringenin with the 
coformers was used. In all cases, a powdered material was isolated and analyzed by powder 
X-ray diffraction (PXRD) and IR (see Supporting Information). 
Solution Crystallization 
Based on the stoichiometric ratio determined from the neat grinding experiments, the 
naringenin and the coformer were mixed in the solid state, dissolved in a 1:4 (v/v) mixture of 
methanol and IPA at ~35 °C in a sample vial, covered with perforated parafilm, and left at 
room temperature until the solvent had completely evaporated, typically 1-2 days. The 
obtained single crystals were suitable for further analysis by SCXRD. 
Physical Measurements 
A Bruker Tensor ATR 37 spectrometer was employed to analyse the compounds using OPUS 
7.2 (Bruker Optics, Ettlingen, Germany).  Samples were placed on diamond probe attenuated 
total reflectance (ATR) crystal accessory, and 32 scans were collected for each sample at a 
resolution of 2 cm-1 over a wavenumber region of 425-4000 cm-1. Differential scanning 
calorimetry (DSC) data were collected using a TA Instruments Q1000. Samples (2-6 mg) 
were crimped in nonhermetic aluminum pans and scanned from 30 to 250 °C at a heating rate 
of 10 °C min–1 under a continuously purged dry nitrogen atmosphere. PXRD data were 
collected using a D2 phaser diffractometer using Cu Kα1 (λ = 1.5406 Å) radiation. Samples 
were analyzed over a 2θ range of 3.5−45° with increments of 0.05° at a rate of 2° min-1. Data 
were evaluated using the DIFFRAC.Eva (Bruker AXS Inc.) software. HPLC analysis was 
performed on an Agilent 1260 Infinity system with a YMC-Pack ODS-A column (250 x 4.6 
mm, 5 µm) at 27 °C, eluting with MeCN : H2O (55:45) at 1 mL
-1, UV detection at 290 nm.  
Samples were filtered through 20 µm filters prior to analysis. Single crystal X-ray data were 
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collected on a Bruker APEX II DUO diffractometer,40 using graphite monochromatized Mo 
Kα (λ = 0.7107 Å) radiation. The CRYSTALS41 and APEX42 suite of programmes, 
incorporating the SHELX suite of programs,43 were used. The structures were solved using 
direct methods and refined by full-matrix least-squares on F2. All non-hydrogen atoms were 
located and refined with anisotropic thermal parameters. For NR-FLV and NR-BiPy, 
standard SHELX refinement procedure was used. Structures NR-4HP, NR-ATA and NR- 
PIP+, were refined in CRYSTALS. The hydrogen atoms were located in a Fourier difference 
map, but those attached to carbon atoms were repositioned geometrically. The hydrogen 
atoms were initially refined with soft restraints on the bond lengths and angles to regularize 
their geometry (C-H in the range 0.93-0.98 Å, N-H to value of 0.86 Å, O-H to value of 
0.82 Å) and Uiso(H) (in the range 1.2-1.5 times Ueq of the parent atom). Then, the hydrogen 
positions were refined as riding. Molecular graphics were prepared in Mercury 3.944 
and Discovery Studio45. Some of the structures experienced disorder in the chiral centre of 
naringenin, in lower or higher extent. The occupancies of the major and minor components 
were refined in CRYSTALS. To stabilize the refinement and to obtain reasonable ADPs, the 
disordered atoms’ bond lengths and angles (command ‘SAME’), anisotropic displacement 
parameters (‘SIMU’) and main directions of movement (‘DELU’) were restrained to be 
similar. Please see the discussion for details. Crystallographic data are presented in Table 1. 





 NR-FLV NR-ATA NR-4HP NR-BiPy 
Formula C19 H22 N2 O5 C30 H22 O7 C22 H20 N2 O6 C20 H17 N1 O6 C25 H20 N2 O5 
MW 358.37 494.47 408.40 367.32 428.43 
Crystal system monoclinic monoclinic monoclinic orthorhombic orthorhombic 
Space group, Z P 21/c, 4 P 21/c, 4 P 21/c, 4 P na21, 4 P bca, 8 
a, Å 9.5718(18) 9.0624(2) 18.0153(5) 8.7644(2) 12.5657(11) 
b, Å 18.849(4) 28.7469(6) 4.88020(10) 33.3301(9) 7.8552(8) 
c, Å 10.520(2) 9.0586(2) 22.0784(6) 5.9207(2) 42.994(4) 
β, ° 109.072(7) 97.2740(10) 104.6790(10) 90 90 
V, Å3 1793.8(6) 2340.92(9) 1877.74(8) 1729.54(8) 4243.8(7) 
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Dc gcm-3 1.327 1.400 1.445 1.411 1.341 
µ, mm-1 0.800 0.827 0.886 0.880 0.778 
2θ range, ° 5.424-67.082 5.16-67.20 4.140-67.126 5.218- 66.972 2.06-67.32 
T, K 296 296 296 296 296 
Total ref. 20437 28481 22652 10463 26071 
Unique ref. 3066 4061 3249 2897 3735 
Obs. ref., I > 2σ(I) 3034 3978 3178 2862 3412 
# Parameters 318 347 299 302 292 
R1 [I > 2σ(I)] 0.0446 0.0555 0.0463 0.0345 0.0604 
wR2 0.0971 0.1302 0.1100 0.0792 0.1747 
S 1.0808 1.065 0.9732 0.9847 1.066 
 
Solubility experiments: 
Slurry experiments were performed for 24 h and the compounds filtered using Whatmann 
filter paper. The filtrate was then filtered using 0.2 µ filters fitted to a 5 mL syringe for HPLC 
analysis. HPLC chromatograms were collected and the solid residue was air dried to 
determine the stability of the solid forms using IR and PXRD. All the slurry experiments and 
standard curves for selected NR solid forms were tested in 20:80 (v/v) ethanol and water 
solvent medium at 27 °C.  
Results and Discussion: 
Five of the 27 investigated coformers successfully formed new multi-component materials 
with naringenin (NR) as evidenced by IR spectroscopy, DSC and PXRD. Four of the forms 
are cocrystals; namely naringenin with flavone (NR-FLV), 4-hydroxypyridine (NR-4HP), 
anthranilamide (NR-ATA) and 4,4′-dipyridyl (NR-Bipy). The fifth form is a salt with 
piperazine (PIP+-NR-). The observed ionization states of these forms correspond to the 
expected ones based on ∆pKa considerations (see Table S1 in Supporting Information). 
All the novel naringenin containing solid forms can be reproduced in the bulk quantities and 
the PXRDs of these compounds are perfectly matching with the theoretical patterns obtained 
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from the single crystal X-ray diffraction analysis, indicating the purity and identity of the 
prepared materials.  
Multicomponent solid form screening was carried out by using IR spectroscopy and followed 
by powder X-ray diffraction (PXRD). In the IR spectroscopy, both blue and red shifts were 
observed for the novel forms, see Table 2.  
Table 2. IR table for NR and its new solid form C=O stretching frequency comparison 










In the case of the flavone cocrystal, there is a red shift observed from 1625 cm-1 to 1614 cm-1, 
which is expected due to the breaking of strong R7
7
 (14) dimeric units in flavone to form new 
monomeric chains with the naringenin molecule in its cocrystal form. 4-Hydroxypyridine 
exists as the 4-(1H)pyridone (tautomeric form of 4-hydroxy pyridine) in its cocrystal and, 
hence, a red shift in N-H bending region from 1588 cm-1 to 1570 cm-1 was observed. 
However, in the case of piperazine salt, due to the single side protonated piperazine, there is a 
clear blue shift observed in the N-H stretching frequency region from 3215 cm-1 to 3335 cm-1 
and in the lower stretching frequency region 1625 cm-1 to 1635 cm-1. 
The DSC thermograms have single sharp endotherms, which indicates that the samples are 
pure (see Supporting Information). There is no evidence for polymorphic transitions. In all 
cases, the melting point of the multicomponent form was between the naringenin and 
coformer, Table 3, in agreement with Bak and Stanton’s observation of cocrystal melting 
points.46 
No strong correlation exists between the melting point of the coformer and the melting points 
of the naringenin multicomponent solid forms (see Figure S45 in Supporting Information). 
Such a correlation could be expected in a series of multicomponent forms of a compound,47 
however, it has been shown on the case of methylephedrine salts that these correlations only 
Page 8 of 23
ACS Paragon Plus Environment





























































exist in isostructural families.48 This is not the case for these multicomponent forms of 
naringenin since they are not isostructural (see below).  
Table 3. Melting points and enthalpies 
Compound name Single compound, °C Cocrystal / Salt, °C ∆H, J g
-1
 
Naringenin 249-252 ---- 129.9 
Anthranilamide 110-113 156-158 93.9* 
Piperazine 109-112 181-184 155.8* 
Flavone 94-97 192-194 100.8* 
4,4′-Bipyridine 111-114 210-213 57.3* 
4-Hydroxypyridine 148-152 213-216 92.3* 
* value for the NR multicomponent form 
Single Crystal X-ray Analysis: 
Good quality single crystals were grown from methanol and isopropyl alcohol medium for 
each of the NR solid forms. The cocrystals of NR with ATA, FLV, and the salt with PIP were 
solved in monoclinic space group P21/c, whereas the cocrystals with 4,4'-Bipy and 4-HP were 
solved in the orthorhombic space groups Pbca and Pna21, respectively. All the novel solid 
forms have 1:1 naringenin:coformer stoichiometry with one of each of the molecules in the 
asymmetric unit. None of the structures were solvated or hydrated.  
All of the structures are centrosymmetric, which correspond to the racemic character of the 
material used. Interestingly, some of the structures experience a disorder in the chiral centre, 
meaning that the structures are in fact racemic solid solutions. The same effect was observed 
for a recent structural analysis of (±)-naringenin,38 although an older structural analysis 
displayed no disorder.37 Examples of similar anomalous racemates include tetramisole, 
carvone and trospium chloride.49-51 For this to be feasible, the molecules of the enantiomers 
need to have similar shapes and non-covalent interactions to allow for a stable crystal lattice 
when they are interchanged. For the structures presented in this work, NR-PIP and NR-4HP 
were modelled in two orientations with the final refined occupancies of 0.57:0.43/0.43:0.57 
and 0.51:0.49/0.49:0.51, respectively. In NR-Bipy and NR-ATA, the disorder was a minor 
component (less than 10 %) that did not allow for a stable refinement of the disorder (the 
disorder causes strong overlaps in the C ring of naringenin) and therefore, the model 
presented has no disorder. The flavone cocrystal was not disordered. 
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Figure 4. The disorder in the chiral centre of naringenin in NR-4HP. 
In the crystal structure of pure naringenin, there is an intramolecular O−H···O=C S(6) 
hydrogen bond involving the carbonyl oxygen atom of the pyrene ring (B) and the adjacent 
hydroxyl group (A). Two naringenin molecules hydrogen bond via O−H···O hydrogen 
bonding involving the remaining hydroxyl group in ring A to form R2
2
 (24) rings, Figure 4. 
The dimeric rings are hydrogen bonded via O−H···O=C hydrogen bonds involving the 
hydroxyl group C. Thus the carbonyl oxygen atom is bifurcated. Combination of these 
hydrogen bonds gives rise to a large R6
6
 (40) ring that contains four naringenin molecules. 
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Figure 5. S(6), R2
2
 (24) and R6
6
 (40) hydrogen bonding present in (±)-naringenin42 
The O−H···O=C S(6) hydrogen bond seen in crystal structure of pure naringenin is preserved 
in all the multicomponent forms, but the cyclic dimers are not retained in all cases. The 
overall crystal packing of naringenin is very different in each and every crystal structure, as 
determined by molecular packing similarity calculation performed in CrystalCMP52 (See 
Figure 16 in Supporting Information). For clarity, the disorder has been omitted from the 
following crystal structures’ description. 
NR-Bipy (1:1) cocrystal: 
In NR-Bipy, the two free phenolic groups on rings A and C form hydrogen bonding network 
by interacting with both nitrogen atoms on bipyridine via O−H···N hydrogen bonding, giving 
rise to H-bonded chains. These chains are aligned only along the c-axis and interconnected 
through C−H···O bonds involving the carbonyl oxygen atom to form 2-D buckled layers, 
Figure 6. This is a commonly seen structural motif in cocrystals of flavonoids containing 
pyridine based coformers.53 
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Figure 6. Crystal structure of NR-Bipy cocrystal; (a) 2D tapes (b) 3D alignment of tapes. 
NR-FLV (1:1) cocrystal: 
Flavone does not contain any moderate hydrogen-bond donors, meaning that molecules are 
connected via weak C-H···O=C and CH-π interactions [CSD reference code WADRAV].54 
In contrast, in NR-FLV, flavone molecules are bridging between naringenin dimers through 
C−H···O and O−H···O=C hydrogen bonding, Figure 7. The R2
2
 (24) ring dimers seen in 
naringenin are replaced by R2
2
 (20) dimers, utilising the hydroxyl group on ring C and the 
keto-oxygen on pyrone ring B, via O−H···O hydrogen boding.  
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Figure 7. Flavone capped naringenin dimers in their co-crystal 
NR-ATA (1:1) cocrystal: 
In NR-ATA, one of the hydrogen atoms on the amine functional group is involved in an S(6) 
intramolecular hydrogen bond with the amide group, whereas this feature hasn’t been seen in 
the reported individual anthranilamide crystal structure [CSD reference code JIXCIC].55 
Thus, only three N−H donors (one from amine and two from amide groups) are available to 
participate in hydrogen bonding with naringenin. 
The amino group with one available N−H forms a centrosymmetric N−H···O, O−H···N 
hydrogen bonded R1
4
 (8) tetramer with the hydroxyl group present on ring C of naringenin, 
Figure 8. The other hydroxyl group (A) forms an O−H···O hydrogen bond with the carbonyl 
oxygen of the amide. The syn H atom of the amide is involved in N−H···O hydrogen bond 
with the hydroxyl oxygen atom of naringenin (A) over the inversion center. The anti H atom 
of the amide group is interacting via N−H···O hydrogen bonding with the carbonyl group of 
the naringenin over the screw axis and generates an infinite H-bond chain consisting of (syn) 
N−H···O−H(intra)···O···H−N(anti), over the 21-screw axis along b and that generates a H-
bond layers parallel to (-1 0 2). The naringenin molecules connecting such hydrogen bond 
layers in the third dimension are arranged head to tail over the inversion center. 
 
(a) 
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Figure 8. Two views of the crystal structure of the naringenin anthranilamide cocrystal 
showing the hydrogen bonding between the two components. 
NR-4HP (1:1) cocrystal: 
The crystal structure of NR-4HP reveals that the 4-hydroxypyridine adopts the stable 
preferred 4-(1H)pyridone tautomer (just one structure found in CSD as 4-hydroxypyridine 
among 12 hits).56 The pyridone molecule is interacting with the carbonyl group of naringenin 
via N−H···O hydrogen bonding via O−H···O hydrogen bonding through its carbonyl oxygen 
atom with the hydroxyl group on C of naringenin located on the core and extends into an 
infinite tape, Figure 9. The phenol side arms of naringenin from pairs of such infinite tapes 
related by a glide plane, interdigitated and connected to carbonyl group of pyridone into a 
ladder via O−H···O hydrogen bonding. Such ladders are arranged parallel and stacked in 
offset mode and hence form 2D layers of ladders. The ladders in such stacked layers are 
connected to ladders in adjacent layers via N−H···O hydrogen bonds to the phenolic oxygen 
which is involved in intramolecular H-bond to form a 3D structure.                   
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Figure 9. Crystal structure of naringenin: 4-hydroxypyridine (as the 4-pyridone tautomer) 





 (1:1) salt: 
The piperazinium NH2
+ group forms a R4
6
 (12) motif involving two deprotonated phenoxides 
and hydroxyl group on C naringenin.  The other N−H group of piperazine forms N−H···O 
hydrogen bonding with the ether oxygen atom of naringenin, Figure 10. 
 
   (a) 
 
           (b) 
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Figure 10. Crystal structure of piperazinium naringeninate. Note that the proton transfer from 
naringenin to piperazine in the R4
6
 (12) hydrogen bond motif involving (two hydroxyl and 
two phenoxide groups). The second NH piperazine is hydrogen bonding with the ether 
oxygen of naringenin. 
Solubility Study 
Solubility studies were undertaken on the viable solid forms (GRAS) of naringenin, namely 
the NR-FLV dual nutraceutical cocrystal and the PIP+-NR- salt. Due to the poor solubility of 
parent naringenin in water, these studies were conducted in an ethanol (20%) water (80%) 
mixture.  
As expected, the solubility experiments on NR- PIP+ salt have shown significant improvement 
in the solubility (632 mg mL-1) in comparison to naringenin (0.2 mg mL-1). NR-FLV 
decomposed within the inital five minutes during the equilibrium solubility study as 
evidenced by IR, HPLC and PXRD data. The PXRD pattern of the dried NR-FLV (residue on 
the filter paper) does not match with any of the known individual forms or cocrystals and 
HPLC analysis of the filtrate showed several components (see Supporting Information).  
During the review process for this manuscript, Luo et al. described cocrystals of naringenin 
with betaine, picolinic acid and isonicotinamide.57 The latter was not discovered in our work, 
however, their work used a different solvent system to this work, which is most likely 
responsible for the different results.  
Conclusions: 
Naringenin was found to form four cocrystals and one salt, all with 1:1 stoichiometry, from 
the 27 coformers investigated. A number of different H-bonded motifs were adopted in these 
multi-component forms reflecting the wide variety of hydrogen bond donors and acceptors in 
the individual components. Some of the structures exhibited disorder in the chiral centre on 
naringenin, and are, in fact, anomalous racemic solid solutions. The structural analysis 
reveals that the S(6) O−H···O=C in naringenin is maintained in all five multicomponent 
forms and that the carbonyl oxygen atom is bifurcated in all four neutral cocrystals. The 
cocrystal with 4-hydroxypyridine reveals that it adopts the 4-(H)-pyridone tautomer in 
agreement with all known solid-state structures involving this system and its simple 
analogues.  
ASSOCIATED CONTENT 
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Supporting Information. IR, PXRD, DSC, HPLC and solubility data, and additional figures. 
The crystallographic data have been deposited with the Cambridge Crystallographic Data 
Center, CCDC deposition numbers: 1836185-1836189. The data can be obtained free of 
charge from the Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif. This material is available free of charge via the 
Internet at http://pubs.acs.org. 
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Cocrystallization studies on Naringenin with 27 coformers have led to the formation of five 
new solid forms: piperazinium salt and four cocrystals with the coformers flavone, 4-
hydroxypyridine, anthranilamide, and 4,4′-bipyridine. Solubility studies on the 
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